RAF1 and hepatocellular carcinoma: Sorafenib, a first-line treatment drug for advanced HCC, can suppress growth of liver tumor by inhibiting Raf-1, B-Raf, VEGFRs 1, 2, and 3 and PDGFR-β 34, 35.